Company Profile

SUVEN PHARMACEUTICALS LTD.

NSE : SUVENPHARBSE : 543064ISIN CODE : INE03QK01018Industry : Pharmaceuticals & DrugsHouse : Private
BSE505.902.2 (+0.44 % )
PREV CLOSE (Rs.) 503.70
OPEN PRICE (Rs.) 506.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 7807
TODAY'S LOW / HIGH (Rs.)504.05 511.50
52 WK LOW / HIGH (Rs.)292 565
NSE506.30 2.25 (+0.45 % )
PREV CLOSE(Rs.) 504.05
OPEN PRICE (Rs.) 509.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 506.30 (366 )
VOLUME 226309
TODAY'S LOW / HIGH(Rs.) 504.00 511.80
52 WK LOW / HIGH (Rs.)291.6 559.35

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.20
TTM EPS (Rs.) 12.12
P/E Ratio 41.73
Book Value (Rs.) 41.84
Face Value (Rs.) 1
MCap (Rs. in Mn) 128784.41
Price/Earning (TTM) 37.85
Price/Sales (TTM) 12.75
Price/Book (MRQ) 12.09
PAT Margin (%) 32.39
ROCE (%) 46.23
Incorporation Year : 2018

Management Info :

Venkateswarlu Jasti - Chairman Venkateswarlu Jasti - Managing Director

Registered Office :

Address : #8-2-334 I, S D E Serene Chambers,6th Floor Road No. 5,Avenue 7, Banjara Hills ,
Hyderabad,
Telangana-500034

Phone : 040 - 2354 9414/ 3311/ 3315

Website : www.suvenpharm.com

Registrar's Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE
NEWS More
11Jun06-11-2021$Suven Pharmaceuticals enters into agreement with CSIR-IICT Suven Pharmaceuticals enters

Suven Pharmaceuticals (SPL), CSIR-Indian Institute of Chemical Technology (CSIR-IICT), Hyderabad and CSIR-National Institute of Interdisciplinary Science & Technology, Thiruvananthapuram have entered into an agreement for the process technology transfer and manufacturing of the anti-COVID drug, Molnupiravir and 2-DG.

The agreements between the parties involve a total fee of Rs 8 lakh plus taxes for the grant of the licenses on non-exclusive basis to SPL. As per the agreement, CSIR IICT also would provide the process know how for the manufacture of new anti-COVID drug 2-DG to treat moderately and severely COVID infected patients to reduce their oxygen dependency.

Suven Pharmaceuticals is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.

Suven Pharmaceuticals (SPL), CSIR-Indian Institute of Chemical..
11Jun06-11-2021$Suven Pharmaceuticals jumps on entering into agreement with CSIR-IICT Suven Pharmaceuticals jumps

Suven Pharmaceuticals is currently trading at Rs. 501.00, up by 20.15 points or 4.19% from its previous closing of Rs. 480.85 on the BSE.

The scrip opened at Rs. 495.20 and has touched a high and low of Rs. 514.35 and Rs. 495.20 respectively. So far 48835 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 565.00 on 26-Apr-2021 and a 52 week low of Rs. 152.50 on 12-Jun-2020.

Last one week high and low of the scrip stood at Rs. 523.90 and Rs. 460.00 respectively. The current market cap of the company is Rs. 12732.07 crore.

The promoters holding in the company stood at 60.00%, while Institutions and Non-Institutions held 12.45% and 27.55% respectively.

Suven Pharmaceuticals (SPL), CSIR-Indian Institute of Chemical Technology (CSIR-IICT), Hyderabad and CSIR-National Institute of Interdisciplinary Science & Technology, Thiruvananthapuram have entered into an agreement for the process technology transfer and manufacturing of the anti-COVID drug, Molnupiravir and 2-DG.

The agreements between the parties involve a total fee of Rs 8 lakh plus taxes for the grant of the licenses on non-exclusive basis to SPL. As per the agreement, CSIR IICT also would provide the process know how for the manufacture of new anti-COVID drug 2-DG to treat moderately and severely COVID infected patients to reduce their oxygen dependency.

Suven Pharmaceuticals is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.

Suven Pharmaceuticals is currently trading at Rs. 501.00, up by..
08Jun06-08-2021$ Corporate Action-Board to consider Dividend Corporate Action-Board to c
2. Dividend The Board recommended a final dividend of Rs. 1.00 per equity share of face value of Rs 1/- each for the year 2020-2021. 3. e-Annual GeneralMeeting and Record date (i). The 3rd e-Annual General Meeting of the members of the Company will be held on Tuesday, August 31, 2021 through VC/ OAVM. (ii).The Board approved the August 17, 2021 as record date for the purposes of the Annual General Meeting and final dividend. The final dividend will be paid on andfrom September 07, 2021, within 30 days from the date of approval by members in the AGM.
2. Dividend The Board recommended a final dividend of Rs. 1.00..
01Jun06-01-2021$ Board Meeting Intimation for Intimation Of Board Meeting Of The Company To Be Held On Tuesday, The 8Th June, 2021 Board Meeting Intimation fo
Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/06/2021 ,inter alia, to consider and approve 1) To consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the fourth quarter and for the year ending March 31, 2021. 2) To consider and recommend a final dividend, if any, for the financial year ending March 31, 2021. Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from 01st April, 2021 as per PIT Code of the Company. Trading window will be opened from 11th June, 2021.
Suven Pharmaceuticals Ltdhas informed BSE that the meeting of t..
01Jun06-01-2021$ Board to consider FY 21 results & Final Dividend on June 08, 2021 Board to consider FY 21 res
Suven Pharmaceuticals Ltd has informed BSE that a Meeting of the Board of Directors of the Company will be held on June 08, 2021, inter alia, to consider and approve the following matter(s): 1. To consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the fourth quarter and for the year ending March 31, 2021. 2. To consider and recommend a final dividend, if any, for the financial year ending March 31, 2021. Further note that TRADING WINDOW for dealing in the securities of the Company is already closed from April 01, 2021 as per PIT Code of the Company. Trading window will be opened from June 11, 2021.
Suven Pharmaceuticals Ltd has informed BSE that a Meeting of th..
Financials More
Rs. in Millions
QTR Mar 21 ANNUAL 21
Net Profit644.513086.47
Gross Profit 868.05 4139.79
Operating Profit 969.94547.59
Net Sales 2591.6510097.19
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 19086.15 (4.92%)
M.Cap ( in Cr)
40556.74
Sanofi India (BSE)
 8367.90 (3.43%)
M.Cap ( in Cr)
19271.79
Alkem Laboratories (BSE)
 3454.55 (3.70%)
M.Cap ( in Cr)
41304.33
Sun Pharma Inds. (BSE)
 774.00 (10.06%)
M.Cap ( in Cr)
185708.53
Divi's Lab (BSE)
 4904.65 (1.20%)
M.Cap ( in Cr)
130203.05
Shareholding Pattern More
PROMOTERS 60 %
MUTUAL FUNDS/UTI 4.47 %
NON-INSTITUTION 26.62 %
FI/BANKS/INSURANCE 0 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes